Noticias de LLY_US
Noticias del mercado
Últimas noticias sobre LLY_US — 1345 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Is Eli Lilly Stock Outperforming the Dow?
Eli Lilly’s Zepbound has been linked with lower health costs, with CEO David Ricks saying the results show the value of investing in obesity treatment
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide), a dual GIP...
Employer insurance coverage for GLP-1 weight-loss drugs is shrinking, yet Eli Lilly just posted a 47% revenue surge. Something underneath the headlines is keeping volumes alive, and it changes how shareholders should read every coverage headline going forward.
Zepbound linked to lower healthcare costs in older adults with obesity
Eli Lilly and Company (LLY) is down 3.7% today. Here is some analysis on what might have caused this
Eli Lilly looks like a strong long-term investment thanks to its booming obesity drugs and Alzheimer's treatment, and to Billionaire Ken Griffin's investment.
Eli Lilly faces a key test as cash flow, obesity medicines, pipeline execution, manufacturing capacity, and earnings quality shape its outlook.
Página 43 de 68